Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Grace UwaseDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110.ORCID 0000-0001-9832-5441
Priya LuthraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Olivia A VogelDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Jyoti BatraGladstone Institute of Data Science and Biotechnology, J. David Gladstone Institutes, San Francisco, CA 94158.
Bruno A La RosaNational Emerging Infectious Diseases Laboratories, Boston University, Chobanian and Avedisian School of Medicine, Boston, MA 02118.
Kathleen C F SheehanDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110.ORCID 0000-0002-3357-8285
Oam KhatavkarDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110.
Jacqueline E PaytonDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110.ORCID 0000-0001-8832-3661
Robert A DaveyNational Emerging Infectious Diseases Laboratories, Boston University, Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0001-9168-2892
Nevan J KroganGladstone Institute of Data Science and Biotechnology, J. David Gladstone Institutes, San Francisco, CA 94158.ORCID 0000-0003-4902-337X
Christopher F BaslerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-4195-425X
Daisy W LeungDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110.ORCID 0000-0002-7189-9557
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110.ORCID 0000-0002-0418-9707
Funding
X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2007 to 2018
$48.8M
The role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PORTNOY, DANIEL A · 2004 to 2025
$45.5M
Virology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2M
Virus CoreU19AI106754 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2013 to 2017
$26.0M
Therapeutics Targeting Filoviral interferon-antagonist and replication functionsU19AI109664 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$15.8M
Molecular mechanisms of immune dysregulation by filoviral interferon U19AI109945 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$9.5M
Novel VP30-host Interactions that Negatively Regulate Ebola Virus InfectionR01AI143292 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K., BASLER, CHRISTOPHER F · 2019 to 2023
$4.0M
Discovery of novel, ubiquitin-regulated mechanisms of TB control by macrophagesR01AI120694 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COX, JEFFERY S, KROGAN, NEVAN J · 2015 to 2019
$3.3M
Defining how ubiquitination of Ebola viral proteins affect host-viral dynamicsF30AI181462 · NIAID · WASHINGTON UNIVERSITY · PI Grace Uwase · 2024 to 2026
$125k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) F30AI181462HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01120943HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI143292NIAID NIH HHS F30 AI181462NIAID NIH HHS P01 AI063302NIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI120694NIAID NIH HHS R01 AI143292NIAID NIH HHS U19 AI106754NIAID NIH HHS U19 AI109664NIAID NIH HHS U19 AI109945NIGMS NIH HHS P50 GM082250
6 · The paper itself
Abstract
Ebola virus (EBOV) is a nonsegmented, negative-sense virus (NNSV) with a single-stranded RNA genome. EBOV encodes for a limited number of proteins and thus depends on host factors to facilitate viral replication and pathogenesis. Of the virus-encoded proteins, multifunctional EBOV VP35 (eVP35) is necessary for host immune evasion and viral RNA synthesis. Previous proteomics studies identified an interaction between eVP35 and the host E3 ubiquitin ligase Mindbomb 2 (MIB2). Here, we show how an NNLNS (Asn-Asn-Leu-Asn-Ser) motif (residues 201 to 205) within eVP35 serves as a binding site for MIB2. This motif is critical for eVP35-dependent inhibition of MIB2-mediated interferon induction. It is also important for EBOV RNA synthesis as MIB2 binding to eVP35 inhibited EBOV minigenome activity. Altogether, these findings highlight the importance of the eVP35 protein and the role of host factors in EBOV infection.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ebola virus VP35 NNLNS motif modulates viral RNA synthesis and MIB2-mediated signaling. · full record | OpenQuestion